Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin

Renal Transplant Infection Clinical Trial

Official title:
Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin

Status Completed

Clinical Trial Summary

Renal transplant candidates who have CMV-specific, CD8+ T-cells, are CMV-seropositive and carry HLA-A1 and/ or HLA- A2 alleles have a high probability to maintain this type of immunity during the three first months after the transplant, despite induction immunosuppressive therapy (thymoglobulin).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Renal Transplant Infection

Clinical Trial Details

NCT number	NCT03147183
Study type	Observational
Source	Maimónides Biomedical Research Institute of Córdoba
Contact
Status	Completed
Phase
Start date	August 9, 2016
Completion date	October 21, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03310255` - Helicobacter Pylori Infection in Renal Transplant Patients	N/A
Completed	`NCT03762473` - Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection	Phase 2
Not yet recruiting	`NCT05926076` - COVID-19 Infection
Withdrawn	`NCT05073822` - NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation	Phase 1/Phase 2
Recruiting	`NCT05756036` - Torque Teno Virus: A Biomarker of Immunosuppression